Clinical Trial Update: Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain [Phase 3]

View source ↗

Summary

Phase 3 trial of oxymorphone extended-release for cancer-related and neuropathic pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neuropathic Pain
• Pain

Drugs mentioned

• Opana ER (oxymorphone)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Chronic Pain, Neuropathic Pain | Phase 3 | Status: COMPLETED